Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiation doses from 51Cr-bleomycin.

J Bialobrzeski, J Liniecki, J Greger

    Nuklearmedizin. Nuclear Medicine
    |April 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2023
    Same author

    Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances.

    Annals of the ICRP·2015
    Same author

    ICRP Publication 113. Education and training in radiological protection for diagnostic and interventional procedures.

    Annals of the ICRP·2011
    Same author

    The effect of interleukin-6 on hepatitis B virus replication in peripheral blood mononuclear cells in vitro.

    Acta virologica·2004
    Same author

    99mTc-HEPIDA plasma clearance as a diagnostic tool. Total plasma v. specific hepatic clearance.

    Nuclear medicine review. Central & Eastern Europe·2003
    Same author

    Pharmacokinetic characteristics of 99mTc-Ethylene-l-dicysteine (99mTc-EC).

    Nuclear medicine review. Central & Eastern Europe·2003

    This study tracked 51Cr-bleomycin retention and doses in rats, rabbits, and humans. While whole-body retention is similar across species, localized 51Cr in liver cell nuclei and DNA significantly increases radiation dose equivalents.

    Area of Science:

    • Nuclear Medicine
    • Radiopharmacology
    • Radiation Dosimetry

    Background:

    • 51Cr-bleomycin is a radiopharmaceutical used for diagnostic imaging.
    • Understanding its biodistribution and dosimetry is crucial for patient safety.
    • Previous studies have investigated its behavior in animal models and humans.

    Purpose of the Study:

    • To characterize the long-term whole-body and organ retention of 51Cr-bleomycin.
    • To calculate radiation doses to organs and the whole body in humans using MIRD methodology.
    • To assess the impact of subcellular distribution and Auger electron emission on internal dosimetry.

    Main Methods:

    • Intravenous injection of 51Cr-bleomycin in rats and rabbits.
    • Whole-body retention, plasma concentration, urinary excretion, and organ retention measurements.

    Related Experiment Videos

  • Application of MIRD methodology for dose calculations in humans, using rat kinetic data.
  • Analysis of subcellular distribution in liver cells and estimation of dose equivalents from Auger electrons.

    • Main Results:

    • Integrated whole-body and organ retention of 51Cr is similar in humans and rabbits, approximately twice that in rats.
    • MIRD doses to organs and whole body are comparable to 67Ga-citrate, with an effective dose equivalent of ~6 mSv for a diagnostic dose.
    • Significant enrichment of 51Cr in liver cell nuclei and DNA leads to substantially higher localized dose equivalents (up to 24 times cell-averaged values).

    Conclusions:

    • While overall body burden is manageable, localized high doses to cellular components like DNA warrant careful consideration.
    • The effective dose equivalent, when considering subcellular distribution and Auger electron effects, can be significantly higher than initial estimates.
    • Further refinement of dosimetry models is needed to accurately reflect the risks associated with radiopharmaceuticals exhibiting subcellular localization.